N1-(5-oxo-5,6,7,8-tetrahydronaphthalen-2-yl)acetamide profile

ID Source	ID
PubMed CID	2780190
CHEMBL ID	1568712
CHEBI ID	170037
SCHEMBL ID	315269

Synonym
n-(5-oxo-7,8-dihydro-6h-naphthalen-2-yl)acetamide
CHEBI:170037
OPREA1_724751
DIVK1C_002069
SDCCGMLS-0066186.P001
CDS1_001029 ,
SR-01000641226-1
n1-(5-oxo-5,6,7,8-tetrahydronaphthalen-2-yl)acetamide
smr000459788
MLS000861004
MAYBRIDGE1_005781
HMS557O17
n-(5-oxo-5,6,7,8-tetrahydronaphthalen-2-yl)acetamide
88611-67-0
AKOS015918160
CCG-51963
HMS2785K16
FT-0629685
PS-4443
6-acetamido-1,2,3,4-tetrahydronaphthalen-1-one
SCHEMBL315269
CHEMBL1568712 ,
6-(acetylamino)-1-tetralone
6-acetamido-tetralone
6-acetamido-1-tetralone
6-acetylamino-1-tetralone
n-(5-oxo-5,6,7,8-tetrahydronaphthalen-2-yl)-acetamide
n-(5-oxo-5,6,7,8-tetrahydro-naphthalen-2-yl)-acetamide
acetamide, n-(5,6,7,8-tetrahydro-5-oxo-2-naphthalenyl)-
n-(5-oxo-5,6,7,8-tetrahydronaphthalen-2-yl)acetamide?
DTXSID90381638
J-523125
ZHA ,
n-(5-oxo-5,6,7,8-tetrahydro-2-naphthalenyl)acetamide
mfcd00099461
n-(5-oxo-5,6,7,8-tetrahydro-2-naphthyl)acetamide
bdbm50495379
AMY24761
SB77605
CS-W022901
SY046986

Class	Description
tetralins	Compounds containing a tetralin skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Potency Measurements

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
ATAD5 protein, partial	Homo sapiens (human)	Potency	29.0810	0.0041	10.8903	31.5287	AID504467
thioredoxin glutathione reductase	Schistosoma mansoni	Potency	31.6228	0.1000	22.9075	100.0000	AID485364
DNA polymerase iota isoform a (long)	Homo sapiens (human)	Potency	89.1251	0.0501	27.0736	89.1251	AID588590
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (2)

Process	via Protein(s)	Taxonomy
chromatin remodeling	Bromodomain adjacent to zinc finger domain protein 2B	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Bromodomain adjacent to zinc finger domain protein 2B	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Process	via Protein(s)	Taxonomy
DNA binding	Bromodomain adjacent to zinc finger domain protein 2B	Homo sapiens (human)
protein binding	Bromodomain adjacent to zinc finger domain protein 2B	Homo sapiens (human)
metal ion binding	Bromodomain adjacent to zinc finger domain protein 2B	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Process	via Protein(s)	Taxonomy
nucleus	Bromodomain adjacent to zinc finger domain protein 2B	Homo sapiens (human)
chromatin	Bromodomain adjacent to zinc finger domain protein 2B	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (21)

Assay ID	Title	Year	Journal	Article
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1065941	Binding affinity to human BAZ2B expressed in Escherichia coli BL21(DE3) by WaterLOGSY NMR analysis	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Targeting low-druggability bromodomains: fragment based screening and inhibitor design against the BAZ2B bromodomain.
AID1065937	Displacement of biotinylated H3Kac14 peptide from human BAZ2B expressed in Escherichia coli BL21(DE3) by CPMG NMR analysis	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Targeting low-druggability bromodomains: fragment based screening and inhibitor design against the BAZ2B bromodomain.
AID1065936	Displacement of biotinylated H3Kac14 peptide from human BAZ2B expressed in Escherichia coli BL21(DE3) by WaterLOGSY NMR analysis	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Targeting low-druggability bromodomains: fragment based screening and inhibitor design against the BAZ2B bromodomain.
AID1065938	Displacement of biotinylated H3Kac14 peptide from human BAZ2B expressed in Escherichia coli BL21(DE3) by STD NMR analysis	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Targeting low-druggability bromodomains: fragment based screening and inhibitor design against the BAZ2B bromodomain.
AID1065943	Binding affinity to human BAZ2B expressed in Escherichia coli BL21(DE3) by STD NMR analysis	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Targeting low-druggability bromodomains: fragment based screening and inhibitor design against the BAZ2B bromodomain.
AID1065940	Displacement of biotinylated H3Kac14 peptide from His6-tagged human BAZ2B expressed in Escherichia coli BL21(DE3) after 30 mins by AlphaScreen assay	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Targeting low-druggability bromodomains: fragment based screening and inhibitor design against the BAZ2B bromodomain.
AID1065942	Binding affinity to human BAZ2B expressed in Escherichia coli BL21(DE3) by CPMG NMR analysis	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Targeting low-druggability bromodomains: fragment based screening and inhibitor design against the BAZ2B bromodomain.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).	2014	Journal of biomolecular screening, Jul, Volume: 19, Issue:6	A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (12.50)	29.6817
2010's	5 (62.50)	24.3611
2020's	2 (25.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	8 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Condition	Relationship Strength	Studies
Innate Inflammatory Response [description not available]	2.05	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.05	1
Plasmodium falciparum Malaria [description not available]	2.1	1
Malaria, Falciparum Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.	2.1	1

N1-(5-oxo-5,6,7,8-tetrahydronaphthalen-2-yl)acetamide

Cross-References

Synonyms (41)

Drug Classes (1)

Protein Targets (4)

Potency Measurements

Inhibition Measurements

Biological Processes (2)

Molecular Functions (3)

Ceullar Components (2)

Bioassays (21)

Research

Studies (8)

Market Indicators

Research Demand Index: 12.17

Study Types

N1-(5-oxo-5,6,7,8-tetrahydronaphthalen-2-yl)acetamide

Cross-References

Synonyms (41)

Drug Classes (1)

Protein Targets (4)

Potency Measurements

Inhibition Measurements

Biological Processes (2)

Molecular Functions (3)

Ceullar Components (2)

Bioassays (21)

Research

Studies (8)

Market Indicators

Research Demand Index: 12.17

Study Types

Related Drugs (1)

Related Conditions (4)